Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Steffen Ormanns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0754-9034; OpenAlex author ID A5022323779. Sources: OpenAlex.

Their work

Papers
48 (first author 3, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
124
Papers, trials and grants by year

2013: 3 papers · 2014: 4 papers · 2015: 2 papers · 2016: 3 papers · 2017: 7 papers · 2018: 4 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 3 papers · 2023: 5 papers · 2024: none · 2025: 7 papers · 2026: 4 papers

Papers 48

  1. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
  2. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Last author DOI 10.1016/j.ejca.2026.117040↗
  3. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  4. Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic P… Co-author DOI 10.1053/j.gastro.2026.04.021↗
  5. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  6. Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients which is mitigated by postoperative antib… Last author DOI 10.1038/s41416-025-03078-2↗
  7. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  8. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreati… Co-author DOI 10.1097/sla.0000000000006210↗
  9. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
  10. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  11. The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Last author DOI 10.3390/biom15030426↗
  12. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  13. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  14. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Last author DOI 10.1038/s41416-023-02295-x↗
  15. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
  16. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. Co-author DOI 10.1200/po.22.00650↗
  17. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. Last author DOI 10.1002/ijc.34044↗
  18. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  19. Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Last author DOI 10.1093/jncics/pkac039↗
  20. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  21. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Co-author DOI 10.1007/s00262-020-02605-9↗
  22. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  23. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Last author DOI 10.1038/s41416-020-01029-7↗
  24. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  25. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Co-author DOI 10.3390/cancers11010039↗
  26. POLE gene hotspot mutations in advanced pancreatic cancer. Last author DOI 10.1007/s00432-018-2746-x↗
  27. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  28. [Chronic Pancreatitis and Pancreatic Cancer - Tumor Risk and Screening]. Co-author DOI 10.1055/s-0043-125407↗
  29. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdy417↗
  30. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Co-author DOI 10.1002/mc.22644↗
  31. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  32. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. First author DOI 10.1038/bjc.2017.115↗
  33. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  34. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. Co-author DOI 10.1093/annonc/mdw564↗
  35. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational resea… First author DOI 10.1186/s12885-017-3376-4↗
  36. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. Co-author DOI 10.3390/ijms18051094↗
  37. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.02.057↗
  38. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  39. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and… Co-author DOI 10.1038/bjc.2016.355↗
  40. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Co-author DOI 10.1007/s13277-014-2885-x↗
  41. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.362↗
  42. ALK expression is absent in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-014-1774-4↗
  43. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK010… Co-author DOI 10.1016/j.ejca.2014.04.023↗
  44. Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. Co-author DOI 10.1038/bjc.2014.60↗
  45. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  46. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00535-013-0767-4↗
  47. Translational Research in Pancreatic Cancer First author DOI 10.1097/mpa.0b013e31829629f6↗
  48. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective eval… Co-author DOI 10.1200/jco.2013.51.0826↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefan Hubert Boeck · 36 shared papers, 2013–2026 · strength 3.76
  2. Volker Heinemann · 35 shared papers, 2013–2026 · strength 3.67
  3. Michael Haas · 28 shared papers, 2013–2025 · strength 2.56
  4. Michael Guenther · 12 shared papers, 2018–2026 · strength 2.31
  5. Jens Werner · 17 shared papers, 2016–2025 · strength 2.18
  6. Stephan Krüger · 24 shared papers, 2014–2025 · strength 1.98
  7. Christoph Benedikt Westphalen · 15 shared papers, 2016–2023 · strength 1.44
  8. Sai Agash Surendran · 5 shared papers, 2022–2026 · strength 1.18
  9. Jan Goesta D’Haese · 8 shared papers, 2018–2025 · strength 1.00
  10. Julia V. Mayerle · 8 shared papers, 2018–2026 · strength 0.92
  11. Georg Beyer · 6 shared papers, 2018–2026 · strength 0.74
  12. Danmei Zhang · 4 shared papers, 2023–2026 · strength 0.72
  13. Volker Kunzmann · 3 shared papers, 2022–2026 · strength 0.63
  14. Bernhard Willibald Renz · 3 shared papers, 2023–2025 · strength 0.56
  15. Matthias Ilmer · 3 shared papers, 2020–2025 · strength 0.52
  16. Brigitte Kimmel · 2 shared papers, 2026 · strength 0.52
  17. Jens Thomas Siveke · 6 shared papers, 2013–2026 · strength 0.52
  18. Lisa Miller‐Phillips · 3 shared papers, 2022–2025 · strength 0.48
  19. Lena Weiss · 3 shared papers, 2023 · strength 0.43
  20. Klara Dorman · 3 shared papers, 2023 · strength 0.43
  21. Stefan Holdenrieder · 5 shared papers, 2015–2023 · strength 0.39
  22. Alexandr V. Bazhin · 3 shared papers, 2018–2025 · strength 0.38
  23. Jen Jen Yeh · 2 shared papers, 2025 · strength 0.37
  24. Christiane J. Bruns · 4 shared papers, 2015–2025 · strength 0.36
  25. Thomas Jens Ettrich · 2 shared papers, 2022–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.